Literature DB >> 666987

Lymphocytic tumours of indeterminate nature: a 5-year follow-up of 98 conjunctival and orbital lesions.

G Morgan, J Harry.   

Abstract

Ninety-eight adnexal lymphocytic tumours of indeterminate nature have been followed up for at least 5 years. Both non-disseminating and disseminating tumours have either very similar or identical histopathological features. It is not possible to make a definitive diagnosis when the lesions are first seen, and a conclusion can be reached only after a prolonged follow-up. The nature of the non-disseminating tumours is unknown.

Entities:  

Mesh:

Year:  1978        PMID: 666987      PMCID: PMC1043239          DOI: 10.1136/bjo.62.6.381

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  2 in total

1.  Lymphocytic tumours of the orbit.

Authors:  G Morgan
Journal:  Mod Probl Ophthalmol       Date:  1975

2.  Lymphocytic tumours of the conjunctiva.

Authors:  G Morgan
Journal:  J Clin Pathol       Date:  1971-10       Impact factor: 3.411

  2 in total
  5 in total

1.  An overview of ocular adnexal lymphoid tumors.

Authors:  F A Jakobiec; D M Knowles
Journal:  Trans Am Ophthalmol Soc       Date:  1989

2.  Gadolinium enhanced magnetic resonance imaging in the diagnosis of anterior visual pathway meningiomas.

Authors:  M G Alper; J L Sherman
Journal:  Trans Am Ophthalmol Soc       Date:  1989

3.  The cytological, immunocytochemical and molecular genetic analysis in diagnosis of the neoplasms of the eye, eye adnexa and orbit.

Authors:  Z Krzystolik; A Rosławska; E Bedner
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

4.  Ocular adnexal lymphoma-comparison of MALT lymphoma with other histological types.

Authors:  M Cahill; C Barnes; P Moriarty; P Daly; S Kennedy
Journal:  Br J Ophthalmol       Date:  1999-06       Impact factor: 4.638

5.  Clinical and radiological presentation of 95 orbital lymphoid tumors.

Authors:  E Polito; P Galieni; A Leccisotti
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.